NLRP3 and atherosclerosis: Activation of NLRP3, a multiprotein inflammasome complex, and its downstream effects on IL-1β maturation appeared to cause this exacerbated atherosclerosis, as the administration of an NLRP3 inhibitor to these mice decreased atherosclerotic plaque size, decreasing the inflammatory impact of Tet2 mutant cells (9).